The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers.
Jetter
Alexander
A
Lazar
Andreas
A
Schömig
Edgar
E
Fuhr
Uwe
U
Kinzig-Schippers
Martina
M
Sörgel
Fritz
F
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001628:Beverages; D032083:Citrus paradisi; D018592:Cross-Over Studies; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D065729:Cytochrome P-450 CYP2C9; D018565:Food-Drug Interactions; D005838:Genotype; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000097:blood / Q000493:pharmacokinetics*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000097:blood
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human